在患有EGFRExon 20插入的晚期非小细胞肺癌患者中解开生存决定因素

相关实验视频

Updated: May 20, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

195

Kung-Yang Wang¹, Shih-Chieh Chang², Yu-Feng Wei^3,4

¹Division of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan.

Current oncology (Toronto, Ont.)

|March 26, 2025

概括

皮表皮生长因子受体 (EGFR) 异位20插入是罕见的肺癌突变. 当标准疗法无法使用或不能耐受时,EGFR氨酸激酶抑制剂 (TKI) 显示出作为替代治疗的潜力.

科学领域:

在瘤学瘤学.
遗传学遗传学是一个
药理学药理学是指药理学的学科.

背景情况:

肺癌是台湾癌症死亡的主要原因之一.
皮表皮生长因子受体 (EGFR) 突变很常见,但外显子20插入代表了一个罕见的子集 (约. 4%) 的情况.
对EGFR氨酸激酶抑制剂 (TKIs) 的反应与EGFR外20插入有显著的差异,需要进一步研究.

研究的目的:

在非小细胞肺癌 (NSCLC) 中分析罕见EGFR突变的临床意义和治疗反应,特别是外20插入.
评估EGFR-TKIs和化疗在EGFR外基子20插入患者的疗效.
在这个患者队列中确定无进展生存 (PFS) 和整体生存 (OS) 的预测因素.

主要方法:

一项回顾性研究,结合了来自台湾多家大型医院的数据.
包括38名被诊断患有NSCLC和EGFR外基因20插入的患者.
对治疗反应的分析,包括PFS和OS,用于各种疗法,如阿法替尼,化疗和第一代EGFR-TKI.

主要成果:

对于EGFR外因子20插入的患者,PFS的中位数为5.15个月,OS的中位数为13个月.
治疗期间的PFS中位数不同:阿法替尼 5.4个月,化疗 5.7个月,第一代EGFR-TKI 4.3个月.
评估了预测因素和生存结果之间的相关性.

结论:

当标准疗法无法使用或无法容忍时,EGFR-TKIs可以被视为EGFR外基因20插入NSCLC的替代治疗方法.
亚法替尼可能是选择患者的可行选择,这取决于特定的突变特征.
需要进一步研究以确定这种罕见突变类型的最佳治疗策略.

关键词:

在 exon 20 中插入了插件.其他非小细胞肺癌.罕见 EGFR 突变突变

相关概念视频

01:21

Cancer Survival Analysis

313

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

313

02:53

Adaptive Mechanisms in Cancer Cells

5.7K

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

5.7K

02:40

Cancer Stem Cells and Tumor Maintenance

4.7K

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

4.7K

01:15

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.

01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...

02:56

Treatment Resistant Cancers

3.2K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...